Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
| العنوان: | Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer |
|---|---|
| المؤلفون: | Miriam Koopman, Cees J van Groeningen, Ninja Antonini, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Otilia Dalesio, Dirk J. Richel, A. Vos, C.J. Rodenburg, Annemieke Cats, Harm Sinnige, Geert Jan Creemers, Cornelis J. A. Punt, Jolien Tol, Emile E. Voest, Frans L. G. Erdkamp, Linda Mol, Jolanda G Schrama, Johan H. J. M. van Krieken |
| المساهمون: | CCA -Cancer Center Amsterdam, Oncology, Other departments, Medical oncology, CCA - Innovative therapy, Faculteit der Geneeskunde |
| المصدر: | New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society The New England Journal of Medicine, 360, 563-72 de Nooy-van Tol, J, Koopman, M, Cats, A, Rodenburg, C J, Creemers, G J M, Schrama, J G, Erdkamp, F L G, Vos, A H, van Groeningen, C J, Sinnige, H A M, Richel, D J, Voest, E E, Dijkstra, J R, Vink-Borger, M E, Antonini, N F, Mol, L, van Krieken, J H J M, Dalesio, O & Punt, C J A 2009, ' Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer ', New England Journal of Medicine, vol. 360, no. 6, pp. 563-572 . https://doi.org/10.1056/NEJMoa0808268Test The New England Journal of Medicine, 360, 6, pp. 563-72 New England Journal of Medicine, 360(6), 563-572. Massachussetts Medical Society The New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society |
| بيانات النشر: | Massachussetts Medical Society, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Oncology, Male, Vascular Endothelial Growth Factor A, Genetics and epigenetic pathways of disease [NCMLS 6], Organoplatinum Compounds, Colorectal cancer, Cetuximab, Kaplan-Meier Estimate, medicine.disease_cause, Deoxycytidine, Immune Regulation [NCMLS 2], Antineoplastic Combined Chemotherapy Protocols, Treatment Failure, Neoplasm Metastasis, Aged, 80 and over, Antibodies, Monoclonal, General Medicine, Middle Aged, Bevacizumab, ErbB Receptors, Oxaliplatin, Female, KRAS, Fluorouracil, Colorectal Neoplasms, medicine.drug, Adult, medicine.medical_specialty, Age-related aspects of cancer [ONCOL 2], Antibodies, Monoclonal, Humanized, Disease-Free Survival, Capecitabine, Proto-Oncogene Proteins p21(ras), Translational research [ONCOL 3], Internal medicine, Proto-Oncogene Proteins, medicine, Humans, neoplasms, Aged, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, Cancer, medicine.disease, digestive system diseases, Surgery, Regimen, Mutation, Quality of Life, ras Proteins, business |
| الوصف: | Contains fulltext : 79995.pdf (Publisher’s version ) (Open Access) BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. METHODS: We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome. RESULTS: The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P=0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wild-type-KRAS tumors or patients with mutated-KRAS tumors in the CB group. CONCLUSIONS: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials.gov number, NCT00208546.) |
| وصف الملف: | application/pdf |
| تدمد: | 1533-4406 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d4f0da267a28af2516fc8e5e361490Test https://doi.org/10.1056/NEJMoa0808268Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....91d4f0da267a28af2516fc8e5e361490 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|